We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.825 | 0.80 | 0.85 | 0.85 | 0.80 | 0.80 | 2,358,877 | 10:31:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.44 | 1.48M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/2/2018 20:11 | And don`t forget that we have N4`s final results next month too. I am looking forward to that as I think it will make for a pleasant read. | hughwilson | |
16/2/2018 20:00 | Parob, We have the might of the Japanese pharma industry attending this conference and they will be listening to Nigel's speech on Nuvec and sitting down at the table with him to discuss collaborations or deals. There can be no way that the market could have digested the significance of that. Any hint of a deal will see N4's shares surge. | hughwilson | |
16/2/2018 19:47 | Perfect place to do business: Cell and gene therapy has become a priority area for the Japanese government. Japan is focused on the need to collaborate with the national and international industry to pursue the commercialisation of new scientific discoveries. This, in parallel with the implementation of the New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorisation of Gene Therapy and Cellular Therapy Products speeding up getting products to the market and facilitating the understanding of regulations by foreign operators promoting translational cooperation, makes Japan an attractive market in this field. Licensing, partnering, outsourcing, development and commercialisation opportunities abound, but collaboration is absolutely critical to the success of each one. | parob | |
16/2/2018 18:22 | Look out for press coverage this weekend. Next week should see a strong performance for N4. | hughwilson | |
16/2/2018 16:56 | jimbobaroony, i suspect that since you said you had sold half your holding at 25, your remaining shares possibly amount to a relatively small position here, so you can afford to be fairly laid back. The actual bid price at the end was over 33p not 32p as quoted PS have a good holiday. | neftanikoff | |
16/2/2018 16:43 | Good luck next week. I'm on holiday so won't be posting. Some of you will miss me I know. I've left my existing holding as is. No stop loss or sell at any price. Fingers crossed I get back and this is at record high. | jimbobaroony | |
16/2/2018 16:35 | Great week guys. Real momentum building here now.Looking forward to next week already! Could the Nuvec point of different news be released whilst they're in Japan!? | parob | |
16/2/2018 16:27 | 100k followed by a 50k buy. MM`s increasing the spread to disguise the strength of the finish. | hughwilson | |
16/2/2018 16:25 | guys welldone , , hope we have an news at the back end of next week rather than early part ,see you next week | falia | |
16/2/2018 16:24 | The 100,000 share trade listed as a sell is in fact a buy from earlier. If institutions have not started buying already, they soon will do. | hughwilson | |
16/2/2018 16:23 | 100K delayed buy now showing from 15.20 | parob | |
16/2/2018 16:22 | another awesome week, now the big week coming up | falia | |
16/2/2018 16:22 | another awesome week, now the big week coming up | falia | |
16/2/2018 16:20 | £5=£10 long term target at the least | falia | |
16/2/2018 16:19 | 10 mins to load up | falia | |
16/2/2018 16:14 | I expect that Myles will put a valuation of at least 3 figures per share and that is only including the additional value of Nuvec. That valuation could be outdated as early as next week if news from Japan starts rolling in. | hughwilson | |
16/2/2018 16:09 | Yup good choice longterm, still plenty to go for!! | escapetohome | |
16/2/2018 16:08 | 35p coming up | falia | |
16/2/2018 15:58 | Just bought in folks, great looking business model, and opportunity. Looking forward to hearing how the company get on next week.Thanks again parob for providing that information yesterday.Gla. | l0ngterm | |
16/2/2018 15:30 | Big old finish looks on the cards IMO. Can't wait until next week! | qs99 | |
16/2/2018 15:27 | Yep, 33p being paid . Massive finish in prospect.. wouldn’t want to be out of these going into the eeekend and into next week... | jakleeds | |
16/2/2018 15:27 | III NNN EEE XXX OOO RRR AAA BBB LLL EEE x 3 Why? Because £3 is my target. | escapetohome | |
16/2/2018 15:26 | Will we see a strong finish today? Looking that way and that will set us up for some weekend press prior to Japan news next week. | hughwilson | |
16/2/2018 15:25 | here comes the boom finish | falia | |
16/2/2018 14:59 | In addition, we are still waiting for updates from both Beaufort and Myles McNulty with regard values. I would expect the valuation from Myles to be much higher as it takes account of near-term future prospects. Myles would have spoken to Nigel prior to his trip to Japan so may have an insight into where this is going. It would not surprise me to see a valuation of well over £1 per share for the near term. | hughwilson |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions